PR Newswire
NEW DELHI, March 24, 2026
NEW DELHI, March 24, 2026 /PRNewswire/ — According to the latest research report published by MarkNtel Advisors, the Global Plasma Fractionation Market is projected to grow at a CAGR of around 6.15% during 2026-2032. The market growth is primarily driven by the increasing prevalence of immunological and hematological disorders, rising demand for plasma-derived therapies, expanding applications of immunoglobulins, and advancements in plasma processing technologies.
https://mma.prnewswire.com/media/2687299/5876657/MarkNtel_Advisors_Logo.jpg
Regionally, North America leads the Global Plasma Fractionation Market, accounting for approximately 54% of the total market share in 2026. The region’s dominance is supported by well-established plasma collection infrastructure, strong presence of leading biopharmaceutical companies, high healthcare expenditure, and increasing awareness regarding plasma-derived therapeutics.
Global Plasma Fractionation Market Key Takeaways
- The Global Plasma Fractionation Market was valued at USD 32.1 billion in 2025 and is projected to grow from USD 35.7 billion in 2026 to USD 51.06 billion by 2032, reflecting steady market expansion driven by rising demand for plasma-derived therapies and growing clinical applications.
- By product type, Immunoglobulins accounted for nearly 60% of the market share in 2026, driven by their extensive use in treating primary and secondary immunodeficiency disorders, autoimmune diseases, and neurological conditions.
- By application, the Immunology segment captured approximately 36% of the Global Plasma Fractionation Market in 2026, supported by increasing diagnosis rates of immune-related disorders and expanding therapeutic indications.
- The presence of leading global and regional biopharmaceutical companies continues to strengthen the competitive landscape through investments in plasma collection networks, product innovation, and advanced fractionation technologies.
Download a FREE PDF Sample of the Report
https://www.marknteladvisors.com/query/request-sample/plasma-fractionation-market.html
(Discover the market potential, emerging technologies, and key industry insights.)
Core Drivers Supporting the Global Expansion of Plasma Fractionation
- Rising Prevalence of Immunological and Rare Disorders
The increasing global burden of immunological and rare disorders is a primary factor driving the demand for plasma-derived therapies. Conditions such as primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), immune thrombocytopenic purpura (ITP), and hereditary angioedema are witnessing a steady rise in diagnosis rates worldwide.
As a result, plasma-derived products, particularly immunoglobulins, have become essential in managing these conditions by enhancing immune response and improving patient outcomes. Furthermore, growing awareness, improved screening programs, and advancements in diagnostic capabilities are contributing to earlier detection and treatment, thereby significantly boosting the demand for these life-saving therapies.
- Growing Demand for Immunoglobulins Across Therapeutic Areas
Building on the rising disease burden, immunoglobulins continue to serve as the cornerstone of plasma fractionation, owing to their extensive application across immunology, neurology, hematology, and infectious disease treatments. The increasing clinical adoption of intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) therapies is further accelerating market growth.
In addition, the growing preference for home-based care and long-term disease management solutions is supporting the rapid uptake of SCIG therapies. This shift not only enhances patient convenience and treatment adherence but also reduces the burden on healthcare facilities, thereby reinforcing the overall demand for immunoglobulin products.
- Advancements in Plasma Processing and Fractionation Technologies
Alongside rising therapeutic demand, continuous advancements in plasma processing and fractionation technologies are playing a crucial role in shaping market growth. Modern techniques such as chromatography, nanofiltration, and advanced viral inactivation methods are significantly improving the purity, safety, and efficiency of plasma-derived products.
Moreover, the integration of innovative filtration systems and hybrid processing technologies is enabling manufacturers to optimize plasma utilization and scale production effectively. These technological improvements are essential in meeting the growing global demand while maintaining stringent safety and quality standards.
Key Obstacles Affecting the Global Plasma Fractionation Market Growth
- Limited Plasma Supply and High Production Complexity
Despite the strong growth outlook, the plasma fractionation market faces notable challenges related to limited plasma supply and the complexity of production processes. Plasma collection remains highly regulated and heavily dependent on donor availability, which can lead to supply constraints and impact product availability.
Furthermore, the fractionation process involves sophisticated infrastructure, rigorous quality control measures, and strict regulatory compliance, all of which contribute to high operational costs. However, increasing investments in plasma collection networks, along with ongoing technological advancements, are expected to gradually alleviate these challenges and support sustainable market expansion in the coming years.
Market Analysis by Product Type, Application & Region
By product type, immunoglobulins dominated the Global Plasma Fractionation Market, accounting for nearly 60% share in 2026, primarily due to their extensive therapeutic applications in treating immune deficiencies, autoimmune disorders, and neurological conditions. Their widespread clinical adoption, coupled with increasing demand for intravenous and subcutaneous formulations, continues to reinforce segment growth. In addition to immunoglobulins, other product categories such as coagulation factor concentrates and albumin are contributing significantly to overall market expansion. These products play a critical role in hemophilia treatment, surgical care, and critical care management, thereby supporting consistent demand across diverse medical settings globally.
By application, the immunology segment held a leading share of approximately 36% in 2026, driven by the rising prevalence of immune deficiencies and autoimmune disorders worldwide. The growing need for effective long-term treatment solutions has significantly increased the adoption of plasma-derived therapies within this segment. Furthermore, advancements in diagnostic capabilities and improved disease awareness are contributing to early intervention and higher treatment rates. Alongside immunology, other application areas such as neurology and hematology are gaining considerable traction, supported by the expanding clinical use of plasma-derived products in managing neurological disorders, bleeding conditions, and other chronic diseases.
Regionally, North America dominated the Global Plasma Fractionation Market, capturing approximately 54% of the total market share in 2026. This leadership is attributed to the region’s advanced healthcare infrastructure, well-established plasma collection networks, and the strong presence of leading biopharmaceutical companies. Additionally, high healthcare expenditure and favorable regulatory frameworks further support market growth in the region.
View Full Report (All Data, In One Place)
https://www.marknteladvisors.com/research-library/plasma-fractionation-market.html
(Explore in-depth analyses, technology trends, and investment opportunities.)
Innovation Momentum Driving Advancements in Plasma Therapies and Patient-Centric Care
The Global Plasma Fractionation Market is witnessing steady progress driven by continuous innovation, regulatory approvals, and a growing focus on enhancing patient convenience. In June 2025, CSL achieved a significant milestone with the U.S. Food and Drug Administration approval of ANDEMBRY® (garadacimab-gxii) for the prophylactic treatment of hereditary angioedema (HAE) in patients aged 12 years and older. Notably, this therapy represents the first treatment targeting factor XIIa at the initiation of the HAE cascade. Its once-monthly, subcutaneous autoinjector format not only reduces the frequency of HAE attacks but also expands preventative treatment options for patients suffering from this rare and potentially life-threatening condition.
Building on this momentum, in July 2025, Takeda announced that the U.S. FDA granted 510(k) clearance for its HyHub™ and HyHub™ Duo vial access devices, designed to simplify the administration of HYQVIA®, a plasma-derived immunoglobulin therapy. These single-use devices are aimed at reducing preparation steps for subcutaneous infusion, thereby improving ease of use in both home and clinical settings. Developed with direct input from patients and caregivers, the devices are expected to be available in the U.S. in the second half of 2025. This advancement underscores the industry’s growing emphasis on patient-centric innovations and improved treatment accessibility.
Major Plasma Fractionation Companies Operating Worldwide
Key companies shaping innovation and competition include:
- CSL Behring
- Grifols, S.A.
- Takeda Pharmaceutical Company Limited
- Octapharma AG
- Kedrion Biopharma
- ADMA Biologics, Inc.
- Bharat Serums and Vaccines Limited
- Intas Pharmaceuticals Ltd.
- Shanghai RAAS Blood Products Co., Ltd.
- Merck KGaA
- Biotest AG
- Emergent BioSolutions Inc.
- Kamada Ltd.
- GC Biopharma Corp.
- PlasmaGen BioSciences Pvt. Ltd.
- LFB
- Syntegon
- Others
Global Plasma Fractionation Market Scope
By Product Type: Immunoglobulins (IVIG, SCIG, Hyperimmune Globulins), Coagulation Factor Concentrates (Factor VIII, Factor IX, Von Willebrand Factor, Prothrombin Complex Concentrates (PCC), Fibrinogen Concentrates, Others), Albumin, Protease Inhibitors (Alpha-1 Antitrypsin, C1 Esterase Inhibitors, Others)By Application: Hematology, Immunology, Neurology, Oncology, Critical Care & Trauma, Pulmonology, Rheumatology, Dermatology, Infectious Diseases, OthersBy Processing Technology: Chromatography, Ultrafiltration & Microfiltration, Nanofiltration & Viral Inactivation, Recombinant/Hybrid ProcessingBy Disease Indication: Primary & Secondary Immunodeficiency, Hemophilia A & B, CIDP, ITP, Kawasaki Disease, Hereditary Angioedema, OthersBy End User: Hospitals & Clinics, Clinical Research Laboratories, Academic InstitutesBy Region: North America, South America, Europe, Middle East & Africa, Asia-Pacific
Browse More Reports
Global Cold Plasma Market:
The Global Cold Plasma Market size was valued at around USD 2.2 billion in 2024 and is projected to reach USD 4.2 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 11% during the forecast period (2025-30).
GCC Geographical Atrophy market
: The GCC Geographical Atrophy Market size was valued at around USD 1.05 billion in 2025 and is projected to grow from USD 1.41 billion in 2026 to USD 5.01 billion by 2032. Along with this, the market is estimated to grow at a CAGR of around 23.63% during the forecast period, i.e., 2026-32.
Saudi Arabia Digital Therapeutics Market
: The Saudi Arabia Digital Therapeutics Market size is valued at around USD 34 million in 2025 and is projected to reach USD 62 million by 2032. Along with this, the market is estimated to grow at a CAGR of around 8.96% during the forecast period, i.e., 2026-32.
Global Digital Therapeutics Market:
The Global Digital Therapeutics Market is estimated to grow at a CAGR of around 20% during the forecast period, i.e., 2024-30.
Global Brachytherapy Devices Market
: The Global Brachytherapy Devices Market is projected to grow at a CAGR of around 7.0% during the forecast period, i.e., 2024-2029.
Global Negative Pressure Wound Therapy Market
: The Global Negative Pressure Wound Therapy Market is projected to grow at a CAGR of around 6.1% during the forecast period, i.e., 2023-28.
Global mRNA Vaccines and Therapeutics Market
: The Global mRNA Vaccines and Therapeutics Market is likely to grow at a CAGR of around 13% during the forecast period, i.e., 2021-26.
About MarkNtel Advisors
MarkNtel Advisors is a leading market research and consulting firm committed to delivering reliable, data-driven insights across diverse global industries. Our research combines extensive primary interviews with industry experts and carefully validated secondary data to ensure accurate and credible market intelligence. With deep sector expertise and a team of experienced analysts, we empower businesses and investors with strategic insights that support informed decision-making in rapidly evolving market environments.
Contact Us:
MarkNtel Advisors
Office No.109, H-159, Sector 63, Noida, Uttar Pradesh – 201301, IndiaContact No: +91 87199 99009Email: [email protected]: marknteladvisors.com
Logo: https://mma.prnewswire.com/media/2687299/5876657/MarkNtel_Advisors_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/plasma-fractionation-market-to-reach-usd-51-06-billion-by-2032–driven-by-rising-demand-for-immunoglobulins-and-growing-prevalence-of-immune-disorders–markntel-advisors-302721886.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…